To Whom It May Concern,

With the submission of this present form, we would like to apply for financing under the European Growth Finance Facility, a quasi-equity financing instrument under the European Fund for Strategic Investments (“EFSI”).

|  |  |
| --- | --- |
| **Legal Name:** |  |
| **Address:** |  |
| **Short Business Description:** |  |
| **Ownership:** |  |
| **Financial figures** | Please, provide some information below only in case there are no audited financial statements available. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| EURm | 2015 | 2016 | 2017 | 2018 |
| Sales |  |  |  |  |
| EBITDA |  |  |  |  |
| EBIT |  |  |  |  |
| Net Income |  |  |  |  |
| Cash from operations |  |  |  |  |
| Capital expenditures |  |  |  |  |
| Dividends/Buybacks |  |  |  |  |
| Cash  |  |  |  |  |
| Tangible assets |  |  |  |  |
| Total assets |  |  |  |  |
| Total financial debt |  |  |  |  |
| Equity |  |  |  |  |
| Full-time employees (FTE) |  |  |  |  |

**Investment programme**

Please, provide an indication of your foreseen investments for the next years. These will provide the basis for an EIB operation.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| EURm | 2019 | 2020 | 2021 | 2022 | 2023 | Total  |
| Capital expenditures |  |  |  |  |  |  |
| R&D costs |  |  |  |  |  |  |
| Operating expenditures |  |  |  |  |  |  |
| Working Capital |  |  |  |  |  |  |
| Other |  |  |  |  |  |  |
| Total costs |  |  |  |  |  |  |
| Estimate split EU/Non-EU | % | % | % | % | % | % |

Example of costs which should be included

* + - 1. The purchase, renovation or extension of tangible assets other than land;
			2. The purchase of patents and licences, where they are necessary for the technical implementation;
			3. Investment in intangible assets, i.e.:- Development, planning and financing costs during the construction phase of a tangible asset;- R&D expenses (fees, development costs and gross salaries directly associated with the research, development, and innovation components of the activity);
			4. Building up of distribution networks in domestic or other markets inside the EU (asset and/or trademark acquisition, operational costs and labour costs);
			5. Medium and long term working capital needs (i.e. permanent increase in net working capital to support company growth).

|  |
| --- |
| Counterparty Eligibility Criteria – please, tick the relevant box(es)The company intends to use the EIB financing to invest in producing or developing products, processes and/or services that are innovative and where there is a risk of technological or industrial failure as evidenced by the business plan. Eligible counterparty shall comply with at least one of the following criteria:  |
| [ ]  | 1. **the company is an SME with less than 250 full-time employees as of the date of this application and it headquarters or its subsidiaries which are expected to receive the financing are located within the EU member states; or**
 |
| [ ]  | 1. **the company should intend to use the EIB financing to invest in producing or developing products, processes and/or services that are innovative and where the business plan indicates a risk of technological or industrial failure, or a business risk; or**
 |
|  | 1. **The company is a “fast-growing enterprise”, as measured by employment or by turnover:**
 |
| [ ]  | 1. The company must demonstrate an average annualised growth in turnover greater than 10% a year, over a three-year period, or
 |
| ☐ | 1. The company must demonstrate an average annualised growth in full-time employees of at least 5% a year, over a three year period (and with one hundred or more employees at the beginning of the observation period); or
 |
|  | 1. **The company shall have a significant innovation potential and/or be an “ Research and Innovation (“R&I”)‑driven enterprise”, satisfying at least one of the following criteria:**
 |
| ☐ | 1. its certified accountant(s) have highlighted R&I expenses/investment in the latest financial statements in an amount at least equal to 5% of its annual turnover;
 |
| ☐ | 1. The company undertakes to spend an amount at least equal to 80% of the EIB loan in R&I expenses/investment in the next 36 months as indicated in its business plan;
 |
| ☐ | 1. it has been formally awarded grants, loans or guarantees from European R&I support schemes (e.g. Horizon 2020 or FP7) or through their funding instruments (e.g. Joint Technology Initiatives, "Eurostars") or through a national or regional research or innovation support schemes over the last 36 months;
 |
| ☐ | 1. it has been awarded an innovation prize over the last 24 months;
 |
| ☐ | 1. it has registered at least one patent in the last 24 months;
 |
| ☐ | 1. it has received an investment from a private-equity fund or from a business angel being a member of a business angel network; or such a private equity fund or business angel is a shareholder of the company at the time of its application for the EIB loan;
 |
| ☐ | 1. it has its registered seat in a science, technology or innovation park or technology cluster or technology incubator, in each case with activities relating to R&I; or
 |
| ☐ | 1. it has benefited from tax credit or tax exemption related to investment in R&I in the last 24 months.
 |
| ☐ | 1. **The company does not meet any of the above conditions but its investment programme is targeting** [**convergence**](http://ec.europa.eu/regional_policy/en/information/publications/maps/2013/eu28-regions-eligible-under-the-convergence-and-regional-competitiveness-objectives) **regions within EU member states.**
 |

Eligible counterparties shall comply with each of the following eligibility criteria:

1. Eligible counterparties shall be micro, small or medium-sized enterprises as defined in the Commission Recommendation 2003/361/EC (OJ L124, 20.05.2003, p. 36), as amended, restated, supplemented and/or substituted from time to time or Mid-caps (defined as enterprises with less than 3,000 employees full-time equivalent);
2. The counterparty shall not be a “firm in difficulty” within the meaning of Article 2.1 of the Community guidelines on State aid for rescuing and restructuring firms in difficulty (OJ C 244, 1.10.2004, p. 2.), as amended, restated, supplemented and/or substituted from time to time(prolonged OJ C 296, 2.10.2012, p.3);
3. The counterparty shall not have a substantial focus on one or more Restricted or Excluded Sectors (which determination shall be made by the Bank in its discretion based, without limitation, on the proportionate importance of such sector on revenues, turnover or client base of the relevant counterparty);
4. The counterparty shall be established and operating in one or several of the EU Member States.

Excluded Activities:

1. production (or construction) of, distribution (or processing) of, and trade in weapons and arms, ammunition, military or police equipment or infrastructures, and equipment or infrastructure which result in limiting people’s individual rights and freedom (i.e. prisons, detention centres of any form) or in violation of human rights;
2. production (or construction) of, distribution (or processing) of, and trade in gambling and related equipment;
3. production (or construction) of, distribution (or processing) of, and trade in tobacco products;
4. activities involving live animals for experimental and scientific purposes insofar as compliance with the "Council of Europe’s Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes" cannot be guaranteed;
5. activities which give rise to environmental impacts that are not largely mitigated and/or compensated;
6. activities considered ethically or morally controversial or which are forbidden by national law, e.g. research on human cloning;
7. pure real estate development activity;
8. pure financial activities e.g. purchasing or trading in financial instruments.

The exclusion and eligibility criteria shall be met at the latest at the time of approval of the EIB loan.

☐ *By checking this box, I acknowledge that in the case of signature of a financing transaction with the EIB, the Borrower’s company name, address and type of financing (i.e. investment loan) will be published on the EIB’s website as stipulated by the Bank’s transparency policy at that time.*

***Visibility****: The Company also undertakes, on a best effort basis and if the context allows it, to include reference to the financing provided by the EIB in its media publications and communication. Reference to EIB should include EIB logo and or standard statement about the EGFF programme and the Bank which can be provided upon request.*

Date: Signature: Name/Title: